single20MG
Chonluten
20MG Protocol
Chonluten 20MG
Injection Freq.
Inject once daily
Cycle Sched.
8–16 weeks; shorter durations (8–12 weeks) acceptable
Reconstitution
3.0 mL BAC water
Modulation of inflammatory and proliferative pathways in macrophage/monocyte cell models
Bronchopulmonary tissue bioregulator concept within peptide literature
Generally favorable tolerability described for similar ultrashort peptides in preclinical settings
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 250 mcg (0.25 mg) | 3.75 |
| 2 | Weeks 3–4 | 500 mcg (0.5 mg) | 7.5 |
| 3 | Weeks 5–6 | 1,000 mcg (1 mg) | 15 |
| 4 | Weeks 7–8 | 1,500 mcg (1.5 mg) | 22.5 |
| 5 | Weeks 9–10 | 2,000 mcg (2 mg) | 30 |
| 6 | Weeks 11–12 | 3,000 mcg (3 mg) | 45 |
| 7 | Weeks 13–14 | 4,000 mcg (4 mg) | 60 |
| 8 | Weeks 15–16 | 4,000 mcg (4 mg) | 60 |
Inject once daily
8–16 weeks; shorter durations (8–12 weeks) acceptable
Chonluten (Glu–Asp–Gly) is described as a short bioregulatory peptide studied within the Khavinson peptide framework with an intended focus on bronchopulmonary tissues. The protocol’s ‘How This Works’ section emphasizes cell-culture findings: in monocyte/macrophage (THP-1) models, Chonluten is reported to modulate proliferative activity and inflammatory pathways at nanomolar concentrations. Rather than a classic single receptor target, the mechanism is framed as regulatory modulation of immune-cell signaling and inflammation-related gene programs. The page also provides a pharmacologic rationale for route selection: ultrashort peptides are described as having poor oral stability and limited mucosal permeability due to enzymatic degradation, which supports subcutaneous injection as a practical delivery method for consistent exposure. Overall, Chonluten is positioned as investigational, with mechanistic support primarily from in vitro studies and broader peptide-bioregulator literature, and with tolerability expected to be favorable aside from possible injection-site irritation.
Mild injection-site reactions (redness/itching)
Limited human clinical evidence (mechanism primarily from preclinical/cell models)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)